A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy

Andre Goy, Andres Forero, Nina Wagner-Johnston, W. Christopher Ehmann, Michaela Tsai, Kiyohiko Hatake, Revathi Ananthakrishnan, Angela Volkert, Erik Vandendries, Michinori Ogura

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences